Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma

  title={Efficacy control of therapy using circulating epithelial tumor cells (CETC) as “Liquid Biopsy”: trastuzumab in HER2/neu-positive breast carcinoma},
  author={Katharina Pachmann and Oumar Camara and Torsten Kroll and Mieczyslaw R. Gajda and Anne-Kathrin Gellner and Jana Wotschadlo and Ingo Bernhard Runnebaum},
  journal={Journal of Cancer Research and Clinical Oncology},
  pages={1317 - 1327}
PurposeThe majority of targeted personalized cancer therapies are effective only in part of the patients, and most of these drugs are excessively expensive. Therefore, methods are urgently required, which reveal already early during treatment, whether the therapy is effective. In the present report, monitoring of circulating epithelial tumor cells (CETC) was used as a timely control of trastuzumab therapy in patients with HER2/neu-positive breast cancer.MethodsSeventy-nine sequential HER2/neu… 

Chemosensitivity Testing of Circulating Epithelial Tumor Cells (CETC) in Vitro: Correlation to in Vivo Sensitivity and Clinical Outcome

It is able to show that chemosensitivity testing of circulating tumor cells provides real-time information about the sensitivity of the tumor present in the patient, even at different times during therapy, and correlates with treatment success.

The Value of Monitoring the Behavior of Circulating Tumor Cells at the End of Endocrine Therapy in Breast Cancer Patients

Individual cases demonstrated that an increase of CTC/CETCs after discontinuation of tamoxifen therapy could be stopped by resuming the endocrine therapy, a statistically significant predictor of relapse free survival.

Circulating tumor cells in breast cancer

This review reviewed 81 manuscripts, and categorized those in discovery datasets, prognostic factors in metastatic breast cancer, identification of clinical utility in early breast cancer and in novel approaches to identify evidence that could be used for prognosis, predictive power to draw this tool to clinical utility.

Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.

The data generated outline the importance of a profiling not only of tumors but also of CTCs to establish individualized treatments and may then appear as new prognosis and treatment marker for both metastatic and adjuvant breast cancers.

Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors

PD-L1 seems to be a major factor in immune evasion and is highly expressed on CETCs regardless of the type of cancer, and may be a promising target of anticancer treatment.

Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer

The cell enrichment and extraction microfluidic technology provides a sensitive platform for evaluation of HER2 gene amplification in CTCs and DTCs.

Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment

Definition of biomarkers based on comprehensive characterization of CTCs has a strong potential to be translated to individualized targeted treatments and spare breast cancer patients unnecessary and ineffective therapies but also to reduce the costs for the health system and to downsize the extent and length of clinical studies.

[Circulating tumor cells: a new challenge for laboratory medicine].

The CellSearch device is the only one which is validated by the FDA for managing metastatic breast, prostate and colo-rectal cancer and was used in most of the studies having demonstrated the prognostic and predictive value of CTCs in many tumoral localizations.

Establishment and Application of Prostate Cancer Circulating Tumor Cells in the Era of Precision Medicine

Because of the lower invasiveness of liquid biopsy using CTCs, it can be performed more frequently; accordingly, personalized disease status can be successively determined at serial time points.

The influence of radioiodine therapy on the number of circulating epithelial cells (CEC) in patients with differentiated thyroid carcinoma - a pilot study.

  • T. WinkensK. PachmannM. Freesmeyer
  • Medicine, Biology
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • 2014
This study indicates that the number of circulating epithelial cells in differentiated thyroid cancer undergo changes in response to radioiodine-therapy, which may induce a short-term release of thyroglobulin in the blood.



The relevance of circulating epithelial tumor cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer.

Responsibility of CETC already during the first cycles of neoadjuvant treatment predicts the final response of the tumor.

Monitoring circulating epithelial tumour cells (CETC) to gauge therapy: in patients with disease progression after trastuzumab persisting CETC can be eliminated by combined lapatinib treatment

In patients with lack of CETC reduction in spite of trastuzumab treatment correlated with disease progression the combination of capecitabine/lapatinib highly efficiently led to rapid elimination of CETCs warranting further monitoring during such studies.

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.

  • K. PachmannO. Camara K. Höffken
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
The results show that peripherally circulating tumor cells are influenced by systemic chemotherapy and that an increase (even after initial response to therapy) of 10-fold or more at the end of therapy is a strong predictor of relapse and a surrogate marker for the aggressiveness of the tumor cells.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.

After a 47-month median follow-up, 1 year of trastuzumab given sequentially after adjuvant chemotherapy was not associated with a statistically significant decrease in the risk of relapse.

Trastuzumab plus chemotherapy: convincing survival benefit or not?

  • C. VogelE. Tan-chiu
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
An overall survival benefit produced by a trastuzumab plus chemotherapy combination over chemotherapy alone is confirmed, and it is believed that paclitaxel administered on a 3-week schedule is unlikely to be the most effective combination for Her-2/neu–amplified MBC for three reasons.

Advances in adjuvant therapy for breast cancer.

The addition of trastuzumab to standard adjuvant chemotherapy regimens led to a 52% reduction in events (ie, recurrent cancer, second primary cancer, or death before recurrence) and a significant improvement in overall survival and highlight the need for accurate HER2 testing to best identify the HER2(+) patients who would benefit from the treatment.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy

The data demonstrate that a biology-based breast cancer classification using estrogen receptor (ER), progesterone receptor (PgR), and HER2 bears independent predictive and prognostic potential.

Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.